foxo4-dri senolytic human trial 2024 2025 The disordered p53 transactivation domain is the target of FOXO4 and the compound FOXO4-DRI Results: What to Expect
FOXO4 DRI Results: What to Expect (2026) What are the recommended dosing regimens, safety monitoring, and clinical trial considerations for senolytic agents such as dasatinib + quercetin, navitoclax, fisetin, and FOXO4DRI? Senolytic Drugs Market Size and Outlook 2031 Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $5.65 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14


